Skip to main content
. Author manuscript; available in PMC: 2021 Mar 1.
Published in final edited form as: J Acquir Immune Defic Syndr. 2020 Mar 1;83(3):202–209. doi: 10.1097/QAI.0000000000002236

Table 2.

Comparison of the viral suppression at 12 months postpartum (the primary MCH-ART trial endpoint) and in the LACE study (between 36–60 months postpartum) among women who had outcomes available at both time points (n=322).

LACE study (36–60 months postpartum)
MCH intervention Standard of care Total
MCH-ART trial (12 months postpartum) VL<50 VL≥50 VL<50 VL≥50 VL<50 VL≥50
VL<50 80 (89) 40 (59) 73 (79) 23 (32) 153 (84) 63 (45)
VL≥50 10 (11) 28 (41) 19 (21) 49 (68) 29 (16) 77 (55)